Medtronic receives FDA clearance for expanded indication of LINQ II™ insertable cardiac monitor for use in pediatric patients ages 2 and older

Rhea-AI Summary

Medtronic plc (NYSE:MDT) has received FDA clearance for the LINQ II Insertable Cardiac Monitor (ICM), marking it the first and only device cleared for long-term monitoring in pediatric patients over the age of 2 with heart rhythm abnormalities. This innovation is significant for pediatric cardiologists, offering critical data for diagnosing and managing heart conditions.

The LINQ II ICM is compact, wireless, and features a battery life of up to 4.5 years. It incorporates AccuRhythm AI algorithms, reducing false alerts significantly while ensuring accurate monitoring.

Positive

• First and only ICM cleared by FDA for pediatric use over age 2.
• LINQ II ICM provides long-term, continuous monitoring for heart rhythm abnormalities.
• AccuRhythm AI algorithms reduce false alerts by 74.1% for AF and 97.4% for pause.
• Battery life of up to 4.5 years enhances patient convenience.
• Supports MRI procedures without removal.

Negative

• None.

The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population

DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the LINQ II™ Insertable Cardiac Monitor (ICM) system is the first-and-only ICM to receive 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use in pediatric patients over the age of 2 who have heart rhythm abnormalities and require long-term, continuous monitoring.

"For pediatric cardiologists who see many young patients needing continuous, long-term monitoring for infrequent or unknown heart rhythm conditions, this expanded indication for the LINQ II ICM is critically important," said Jennifer Silva, M.D., director of pediatric cardiac electrophysiology at Washington University in St. Louis and St. Louis Children's Hospital. "The data generated from these small monitors can help us better tailor treatment decisions and ongoing management for our patients."

The LINQ II system is a small (one-third the size of a AAA battery), wireless ICM for patients with abnormal heart rhythms who experience infrequent symptoms including dizziness, palpitations, syncope (fainting) and chest pain, thereby requiring long-term monitoring or ongoing management. The LINQ II ICM, which has a battery life of up to 4.5 years¹, allows patients to undergo magnetic resonance imaging (MRI) when needed, and, as an implantable device, does not interfere with daily activities such as showering, bathing, or swimming. The latest-generation device has been implanted in thousands of patients globally since it was first commercialized in 2020.

"As a result of this milestone, physicians will be able to provide actionable data to help diagnose underlying heart conditions and define treatment protocols in our younger patients with abnormal heart rhythms," said Julie Brewer, president of the Cardiovascular Diagnostics and Services business, which is part of the Cardiovascular Portfolio at Medtronic. "And parents can have peace of mind knowing their child's heart is being monitored continuously, and their doctor will be notified of abnormal heartbeats."

The LINQ II ICM system also includes the recently launched AccuRhythm™ AI algorithms, which applies artificial intelligence (AI) to heart rhythm event data collected by the LINQ II ICM, improving the accuracy of information physicians receive so they can better diagnose and treat abnormal heart rhythms. The two AI algorithms have shown to reduce the number of false alerts specific to the most common ICM false alerts — atrial fibrillation (AF) and pause (asystole) — by 74.1% and 97.4% respectively,^{2, 3} while preserving more than 99% of true alerts.^{4, 5}

With integrated remote patient management, patients or their caregivers can choose to use their smartphones with the LINQ II ICM to automatically transfer device data via the MyCareLink Heart™ mobile app using BlueSync™ technology that enables secure communication via Bluetooth.

Medtronic has been a pioneer in the development of insertable cardiac monitors for more than 20 years; to date, more than 1.7 million patients have received a Medtronic ICM.⁶

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

References:

¹ Nominal settings. LINQ II™ LNQ22 ICM clinician manual. M974764A001D.
² Radtke A, Ousdigian KT, Haddad TD, et al. Artificial Intelligence Enables Dramatic Reduction of False Atrial Fibrillation Alerts from Insertable Cardiac Monitors. Heart Rhythm Journal. Published online August 1, 2021.
³ Cheng YJ, Ousdigian KT, Koehler J, et al. Innovative Artificial Intelligence Application Reduces False Pause Alerts while Maintaining Perfect Trye Pause Sensitivity for Insertable Cardiac Monitors. Presented at Heart Rhythm Society Conference July 31, 2021.
⁴ The pause algorithm preserved 100% of true pause alerts.
⁵ The AF algorithm preserved 99.3% of true AF alerts.
⁶ Medtronic Reveal™ Publications. Medtronic data on file. 2022.

 

Contacts:
Joey Lomicky	Ryan Weispfenning
Public Relations	Investor Relations
+1-612-239-1823	+1-763-505-4626

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-receives-fda-clearance-for-expanded-indication-of-linq-ii-insertable-cardiac-monitor-for-use-in-pediatric-patients-ages-2-and-older-301626708.html

SOURCE Medtronic plc

FAQ

What is the significance of the FDA clearance for the LINQ II ICM for Medtronic (MDT)?

The FDA clearance allows the LINQ II ICM to be used for continuous monitoring in pediatric patients over the age of 2, significantly expanding its market potential.

When was the FDA clearance for LINQ II ICM announced by Medtronic (MDT)?

The FDA clearance was announced on September 20, 2022.

How does the LINQ II ICM improve heart rhythm monitoring for pediatric patients?

The LINQ II ICM provides long-term monitoring and utilizes AI algorithms to reduce false alerts, improving diagnosis and treatment for pediatric patients.

What advancements does the LINQ II ICM offer compared to previous models?

The LINQ II ICM is smaller, has a longer battery life, and includes advanced AI algorithms for more accurate monitoring.

How many patients have received Medtronic's insertable cardiac monitors?

Medtronic has provided insertable cardiac monitors to over 1.7 million patients worldwide.